<DOC>
	<DOCNO>NCT02046616</DOCNO>
	<brief_summary>This open-label , single-arm study evaluate safety , efficacy , tolerability subcutaneously administer RoActemra/Actemra ( tocilizumab ) monotherapy combination methotrexate ( MTX ) non-biologic disease-modifying antirheumatic drug ( DMARDs ) patient active rheumatoid arthritis na√Øve RoActemra/Actemra . Patients receive RoActemra/Actemra 162 mg subcutaneously weekly 24 week .</brief_summary>
	<brief_title>A Study Subcutaneous RoActemra/Actemra ( Tocilizumab ) Patients With Active Rheumatoid Arthritis Inadequate Response Disease-Modifying Antirheumatic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Active rheumatoid arthritis ( RA ) accord revise ( 1987 ) ACR criterion EULAR/ACR ( 2010 ) criterion Moderate severe RA DAS28ESR &gt; 3.2 Inadequate response and/or intolerance MTX nonbiologic DMARDs and/or MTX nonbiologic DMARDs inappropriate Oral corticosteroid ( &lt; /= 10 mg/day prednisolone equivalent ) nonsteroidal antiinflammatory drug ( NSAIDs ) permit stable dose regimen &gt; /= 4 week prior baseline Permitted DMARDs allow stable dose least 4 week prior baseline Receiving treatment outpatient basis , include RoActemra/Actemra Females childbearing potential male female partner childbearing potential must agree use reliable mean contraception define protocol Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow baseline Rheumatic autoimmune disease RA Functional Class IV define ACR Classification Functional Status Rheumatoid Arthritis Diagnosis juvenile idiopathic arthritis juvenile RA and/or RA age 16 Prior history current inflammatory joint disease RA Exposure RoActemra/Actemra biologic DMARDs time prior baseline Treatment investigational agent within 4 week ( 5 halflives investigational drug , whichever long ) screen Intraarticular parenteral corticosteroid within 4 week prior baseline History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody Evidence serious concomitant disease disorder Known active current history recurrent infection Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week screen Active TB require treatment within previous 3 year Positive hepatitis B hepatitis C Primary secondary immunodeficiency ( history currently active ) Pregnant lactate woman Neuropathies condition might interfere pain evaluation Inadequate hematologic , renal liver function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>